Literatur
Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2:96–101
Ayata A, Tatlipinar S, Kar T, Unal M, Ersanli D, Bilge AH (2009) Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 93:79–82
Azad AD, Zhou M, Afshar AR, Bakri SJ, Pershing S (2021) Systemic corticosteroid use after central serous chorioretinopathy diagnosis. Ophthalmology 128:121–129
Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–792.e2
Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237
Bonini Filho MA, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK (2015) Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899–906
Borrelli E, Sarraf D, Freund KB, Sadda SR (2018) OCT angiography and evaluation of the choroid and choroidal vascular disorders. Prog Retin Eye Res 67:30–55
Bousquet E, Beydoun T, Rothschild P‑R, Bergin C, Zhao M, Batista R, Brandely M‑L, Couraud B, Farman N, Gaudric A et al (2015) Spironolactone for nonresolving central serous chorioretinopathy. Retina 35:2505–2515
Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A (2018) Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina 38(3):629–638. https://doi.org/10.1097/IAE.0000000000001580
Bujarborua D (2001) Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 79:417–421
Bujarborua D, Chatterjee S, Choudhury A, Bori G, Sarma AK (2005) Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 25:422–429
Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351
Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2010) Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 4:899–903
Cakir B, Reich M, Lang S, Bühler A, Ehlken C, Grundel B, Stech M, Reichl S, Stahl A, Böhringer D et al (2019) OCT angiography of the choriocapillaris in central serous chorioretinopathy: a quantitative subgroup analysis. Ophthalmol Ther 8:75–86
Chan W‑M, Lam DSC, Lai TYY, Tam BSM, Liu DTL, Chan CKM (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458
Chan W‑M, Lai TYY, Lai RYK, Liu DTL, Lam DSC (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765
Chen S‑N, Hwang J‑F, Tseng L‑F, Lin C‑J (2008) Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 115:2229–2234
Chen ZJ, Lu SY, Rong SS, Ho M, Ng DS‑C, Chen H, Gong B, Yam JC, Young AL, Brelen M et al (2021) Genetic associations of central serous chorioretinopathy: a systematic review and meta-analysis. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2021-318953
Cheng C‑K, Chang C‑K, Peng C‑H (2017) Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37:325–333
Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:14–33
Chong C‑F, Yang D, Pham TQ, Liu H (2012) A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep 2012:bcr2012006970. https://doi.org/10.1136/bcr-2012-006970
Chuang EL, Sharp DM, Fitzke FW, Kemp CM, Holden AL, Bird AC (1987) Retinal dysfunction in central serous retinopathy. Eye (Lond) 1(1):120–125
Chung Y‑R, Seo EJ, Lew HM, Lee KH (2013) Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond) 27:1339–1346
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003
Daruich A, Matet A, Marchionno L, De Azevedo J‑D, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37(10):1905–1915. https://doi.org/10.1097/IAE.0000000000001443
Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995) In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36:718–729
Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR (2003) Central serous chorioretinopathy in African Americans. J Natl Med Assoc 95:553–559
van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy. Ophthalmology 125:1547–1555
Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829–834
Fok ACT, Chan PPM, Lam DSC, Lai TYY (2011) Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 46:160–163
Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB (2011) Finasteride for chronic central serous chorioretinopathy. Retina 31:766–771
French DD, Margo CE (2010) Central serous chorioretinopathy and phosphodiesterase‑5 inhibitors: a case-control postmarketing surveillance study. Retina 30:271–274
Gäckle HC, Lang GE, Freissler KA, Lang GK (1998) Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe 95:529–533
de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650–656
Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63:1–139
Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747
Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820
Haimovici R, Rumelt S, Melby J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698–703
Heinrich MR (1974) Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr 74:681–683
Ho M, Lai FHP, Ng DSC, Iu LPL, Chen LJ, Mak ACY, Yip Y, Cheung C, Young AL, Brelen M (2021) Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol 105:555–560
Hu J, Qu J, Li M, Sun G, Piao Z, Liang Z, Yao Y, Sadda S, Zhao M (2021) Optical coherence tomography angiography-guided photodynamic therapy for acute central serous chorioretinopathy. Retina 41:189–198
Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 253:1889–1897
Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S (2003) Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 23:1–7 (quiz 137–138)
Jain AK, Kaines A, Schwartz S (2010) Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 248:1037–1039
de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570
Katsimpris JM, Pournaras CJ, Sehgelmeble CW, Petropoulos IK (2007) Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 245:460–463
Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A (2013) Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye 27(5) 612–620. https://doi.org/10.1038/eye.2013.24
Kim KS, Lee WK, Lee SB (2014) Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol 157:366–373.e1
Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A (2003) Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 87:709–712
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115:169–173
Koss MJ, Beger I, Koch FH (2012) Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond) 26:307–314
Kozak I, Oster SF, Cortes MA, Dowell D, Hartmann K, Kim JS, Freeman WR (2011) Clinical Evaluation and Treatment Accuracy in Diabetic Macular Edema Using Navigated Laser Photocoagulator NAVILAS. Ophthalmol 118(6) 1119–1124. https://doi.org/10.1016/j.ophtha.2010.10.007
Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG, MINERVA study group (2018) Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina 38(8):1464–1477. https://doi.org/10.1097/IAE.0000000000001744
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C (2015) Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol 200:25–29
Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34:87–97
Leaver P, Williams C (1979) Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 63:674–677
Lee H, Lee J, Chung H, Kim HC (2016) Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina 36:1372–1380
Lim JI, Spee C, Hinton DR (2010) A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 30:1472–1478
Lipowski ZJ, Kiriakos RZ (1971) Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics 12:398–401
Liu B, Deng T, Zhang J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9–19
Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395:294–303
Ma J, Meng N, Xu X, Zhou F, Qu Y (2014) System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 92:e594–e601
Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117:1792–1799
Matet A, Daruich A, Zola M, Behar-Cohen F (2018) Risk factors for recurrences of central serous chorioretinopathy. Retina 38(7):1403–1414. https://doi.org/10.1097/IAE.0000000000001729
Matsumoto H, Kishi S, Otani T, Sato T (2008) Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 145:162–168
Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946
Mohabati D, van Rijssen TJ, van Dijk EH, Luyten GP, Missotten TO, Hoyng CB, Yzer S, Boon CJ (2018) Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol 12:1061–1070
Mohabati D, Hoyng CB, Yzer S, Boon CJF (2020a) Clinical characteristics and outcome of posterior cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 40:1742–1750
Mohabati D, Boon CJF, Yzer S (2020b) Risk of recurrence and transition to chronic disease in acute central serous chorioretinopathy. Clin Ophthalmol 14:1165–1175
Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126
Nicholson BP, Atchison E, Idris AA, Bakri SJ (2018) Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol 63(1):1–8. https://doi.org/10.1016/j.survophthal.2017.06.008
Nicolò M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153:474–480.e1
Nielsen JS, Jampol LM (2011) Oral mifepristone for chronic central serous chorioretinopathy. Retina 31:1928–1936
O’Keefe JH, Abuissa H, Pitt B (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 10:492–497
Park D‑G, Jeong S, Noh D, Sagong M (2021) Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy. Br J Ophthalmol 105:844–849
Peiretti E, Ferrara DC, Caminiti G, Mura M, Hughes J (2015) Choroidal neovascularization in caucasian patients with longstanding central serous chorioretinopathy. Retina 35:1360–1367
Piccolino FC, De La Longrais RR, Manea M, Cicinelli S (2008) Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 28:1008–1012
Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P, Central Serous Chorioretinopathy Study Group (2017) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 37(5):1115–1125
Pikkel J, Beiran I, Ophir A, Miller B (2002) Acetazolamide for central serous retinopathy. Ophthalmology 109:1723–1725
Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators (2008) Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 118:1643–1650
Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM (2015) Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 160:581–587.e1
Rabiolo A, Bandello F (2020) Eplerenone is not superior to placebo for chronic central serous chorioretinopathy. Lancet 395:252–253
Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A (2011) The effect of helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 17:99–103
Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ et al (2018) A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ECSELSIOR). Retina 38(5):962–969
Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F et al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315.e2
Reich M, Boehringer D, Rothaus K, Cakir B, Bucher F, Daniel M, Lang SJ, Lagrèze WA, Agostini H, Lange C (2020) Swept-source optical coherence tomography angiography alleviates shadowing artifacts caused by subretinal fluid. International Ophthalmology 40(8):2007–2016. https://doi.org/10.1007/s10792-020-01376-7
van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF (2018) Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 256:1395–1402
van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S et al (2019a) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770
van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, Keunen JEE, MacLaren RE, Querques G, Fauser S et al (2019b) Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report no. 3. Am J Ophthalmol 205:1–10
van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, MacLaren RE, Downes SM, Fauser S et al (2020) Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial. Am J Ophthalmol 216:80–89
van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, Keunen JEE, MacLaren RE, Hoyng CB et al (2021) Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. Acta Ophthalmol. https://doi.org/10.1111/aos.14775
Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466
Rouvas A, Stavrakas P, Theodossiadis PG, Stamatiou P, Milia M, Giannakaki E, Datseris I (2012) Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol 22(3):417–422
Sacconi R, Baldin G, Carnevali A, Querques L, Rabiolo A, Marchini G, Bandello F, Querques G (2018) Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Eye (Lond) 32:734–742
Sacconi R, Borrelli E, Querques G (2020) Eplerenone for chronic central serous chorioretinopathy. Lancet 396:1556
Sadda SR (2020) Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. Eye (Lond) 34:1489–1490
Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P (2015) Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 12:CD11841
Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528–1555
Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S et al (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 35:859–867
Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M (2017) Eplerenone for chronic central serous chorioretinopathy—a randomized controlled prospective study. Acta Ophthalmol 95(7):e610–e618. https://doi.org/10.1111/aos.13491
Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303–309.e1
Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP, Gopalakrishnan M, Bhende P, Bhende M, Shetty NS, Baluswamy S (2004) Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 111:1708–1714
Shin MC, Lim JW (2011) Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 31:1937–1943
Shinojima A, Hirose T, Mori R, Kawamura A, Yuzawa M (2010) Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina 30:193–202
Shinojima A, Sawa M, Sekiryu T, Oshima Y, Mori R, Hara C, Sugano Y, Kato A, Asato H, Yuzawa M et al (2017) A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. Ophthalmologica 237:159–166. https://doi.org/10.1159/000455807
Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, Loewenstein A, Goldstein M (2016) Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254:15–22
Siedlecki J, Schworm B, Priglinger SG (2019) The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 3:1013–1015
Siegfried F, Rommel F, Rothe M, Brinkmann MP, Sochurek JAM, Freitag J, Grisanti S, Ranjbar M (2019) Evaluating diurnal changes in choroidal sublayer perfusion using optical coherence tomography angiography. Acta Ophthalmol 97:e1062–e1068
Spaide RF, Klancnik JM (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112:825–833
Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996a) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103:2070–2079 (discussion 2079–2080)
Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996b) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16:203–213
Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM (2021) Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res. https://doi.org/10.1016/j.preteyeres.2021.100973
Spitznas M (1986) Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 224:321–324
Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, Sen E, Ozdal P, Ozturk F (2014) Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int J Ophthalmol 7:350–354
Tseng C-C, Chen S-N (2015) (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99(8):1070–1077. https://doi.org/10.1136/bjophthalmol-2014-305353
Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R (2013) Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 251(7):1697–1705
Venkatesh R, Pereira A, Jayadev C, Prabhu V, Aseem A, Jain K, Bavaharan B, Yadav NK, Chhablani J (2020) Oral eplerenone versus observation in the management of acute central serous chorioretinopathy: a prospective, randomized comparative study. Pharmaceuticals 13:170
Verma L, Sinha R, Venkatesh P, Tewari H (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol 4:15
Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina 33:1659–1672
Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF (2000) Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 238:76–80
Wong R, Chopdar A, Brown M (2004) Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy. Eye (Lond) 18:262–268
Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV (2017) Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina 37:1021–1033
Wu ZHY, Lai RYK, Yip YWY, Chan WM, Lam DSC, Lai TYY (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 31:1378–1386
Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA (2014) Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 34:705–712
Yannuzzi LA (1986) Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 84:799–845
Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA (1984) Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 91:1554–1572
Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DLL, Huang SJ, Klancnik JM, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23:288–298
Zhao M, Célérier I, Bousquet E, Jeanny J‑C, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F et al (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122:2672–2679
Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y et al (2015) A 50 % vs 30 % dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol 133:333
Redaktionskomitee der vorliegenden ergänzenden Stellungnahme
Clemens Lange (Münster/Freiburg; federführend); B. Bertram (Aachen); D. Pauleikhoff (Münster)
Redaktionskomitee der Erststellungnahme 2018
Clemens Lange, Freiburg (federführend)
F. Treumer, Kassel
B. Bertram, Aachen
N. Feltgen, Göttingen
H. Hoerauf, Göttingen
D. Pauleikhoff, Münster
J. Roider, Kiel
Author information
Authors and Affiliations
Consortia
Ethics declarations
Interessenkonflikt
Siehe Tab. 1 im Anhang.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Diese Leitlinie erscheint ebenfalls in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, Georg Thieme Verlag, Stuttgart.
Das Redaktionskomitee dieser Stellungnahme wird am Beitragsende gelistet.
QR-Code scannen & Beitrag online lesen
Anhang
Anhang
(siehe Tab. 1)
Rights and permissions
About this article
Cite this article
Berufsverband der Augenärzte Deutschlands e. V. (BVA)., Deutsche Ophthalmologische Gesellschaft (DOG). & Retinologische Gesellschaft e. V. (RG). Stellungnahme von BVA, DOG und RG zur Chorioretinopathia centralis serosa (CCS). Ophthalmologe 119, 148–162 (2022). https://doi.org/10.1007/s00347-021-01549-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-021-01549-4